Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.
EP. 1: Apalutamide in Patients with mCSPC: Background
Neeraj Agarwal, MD, and Simon Chowdhury, MD, examine the efficacy and safety data presented in the recent publication, “Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.”
EP. 2: Apalutamide in Patients With mCSPC: Survival
Drs Agarwal and Chowdhury analyze the survival data from the phase 3 TITAN study of apalutamide in men with mCSPC.
EP. 3: The TITAN Study: Secondary End Points
Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.
EP. 4: Apalutamide in Patients With mCSPC: Safety
GU oncologists discuss toxicities from androgen deprivation therapy and apalutamide as reported in the phase 3 TITAN study.
EP. 5: Key Takeaways for Use of Apalutamide With Androgen Deprivation Therapy
Genitourinary oncology experts share key takeaways and considerations for treating patients with metastatic castration-sensitive prostate cancer.
EP. 6: Future Directions and Novel Combination Therapies for mCSPC
Drs Agarwal and Chowdhury discuss future directions for mCSPC, including potential use of triplet combination therapy.
EP. 7: The Role of Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
2 Clarke Drive Cranbury, NJ 08512